Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › JBCHEPHARM

JBCHEPHARM

JB Chemicals & Pharmaceuticals Limited
Small-capPharma ↗

What the six lenses say about JBCHEPHARM — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2444.5
2026-07-10
VWAP · 1Y anchor
₹1941
+25.9% from VWAP
P/E · TTM
54.1×
TTM EPS ₹45.2
52-week range
100%
position low→high
RSI(14)
81
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How JBCHEPHARM’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.0
avg conviction decile
Leadership
1/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD9100›

The actual numbers

Price vs VWAP (1y)+25.9%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+21.8%
Price vs 50-EMA+10.1%
RSI(14)81
RS vs Nifty 500 · 3M+18.6%
RS vs sector · 3M+6.1%
52-week range100%
Volume vs 30d avg1.23×
Volume vs 60d avg1.30×
ATR(14) · volatility58.0
Bollinger width · vol contraction0.145
FundamentalD760›

The actual numbers

Return on equity (ROE)18.9%
Return on capital (ROCE)25.4%
Operating margin23.1%
Net margin17.1%
Revenue growth · YoY+5.9%
EPS growth · YoY+6.4%
Debt / equity0.00×

Full 8-quarter history in the financials table below.

ValuationD13›

The actual numbers

P/E (TTM)54.1×
TTM EPS₹45.2
52-week range100%
CatalystD229›

The actual numbers

Earnings & momentum33
Capital actions9
Governance53

Every filing in the corporate-announcements panel below.

FlowD550›

The actual numbers

Promoter holding48.8%
Delivery · 30d avg59.0%
Up/down-day asymmetry1.4pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D5 ) ÷ 2 = 7.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 7.0/10
Conviction score95/100›
TechnicalD9›
FundamentalD7›
ValuationD1›
CatalystD2›
FlowD5›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.0pp
+6.2pp
+7.8pp
+22.3pp
+36.1pp
+56.9pp
Nifty 500
Broad-market baseline
-0.4pp
+6.1pp
+7.2pp
+18.6pp
+31.1pp
+53.1pp
Sector
Own-sector index
—
—
+4.8pp
+6.1pp
+16.7pp
+35.2pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

JBCHEPHARM daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2444.50+8.70

Relative strength

RS vs baseline · rebased to 100

JBCHEPHARM ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
141.00-0.56

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,0041,0019639491,0941,0851,065904
↳ change QoQ—-0.4%-3.7%-1.5%+15.3%-0.8%-1.8%-15.1%
EBITDA (₹cr)286280263226301310296201
EBITDA margin28.5%28.0%27.3%23.8%27.5%28.6%27.8%22.2%
PAT (₹cr)177175162146202208198101
↳ change QoQ—-1.3%-6.9%-10.1%+38.4%+3.0%-4.8%-49.0%
Net margin17.6%17.4%16.9%15.4%18.5%19.2%18.6%11.2%
EPS (₹)11.3911.2410.469.3612.9713.2712.636.31
D/E————————
YoY growth · Mar '26Revenue -4.7% YoYPAT -30.8% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 15 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Jun '26
    HIGHearnings
    Reply to Clarification- Financial results
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 Jun '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Jun '26
    MEDIUMgovernance
    Resignation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 May '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 May '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    HIGHearnings
    Clarification - Financial Results
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 11 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 7 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Apr '26
    MEDIUMgovernance
    Cessation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Mar '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds JBCHEPHARM

Mutual funds holding JBCHEPHARM (10)

FundWeightAUM ₹crGrade
Kotak Midcap Reg Gr1.64%67,611
Axis Midcap Gr0.65%32,852
Axis ELSS Tax Saver Fd Gr0.76%31,023
Axis Small Cap Fund Reg Gr2.32%27,840
Kotak Small Cap Reg Gr0.88%18,691
Edelweiss Mid Cap Gr0.58%16,849
Canara Robeco Small Cap Reg Gr2.23%13,967
Canara Robeco Flexi Cap Reg Gr0.97%13,328
Axis Multicap Reg Gr0.74%9,938
Nippon India Flexi Cap Reg Gr1.27%9,590

ETFs holding JBCHEPHARM (9)

ETFWeightGrade
DSP Nifty500 Flexicap Quality 30 ETF3.40%
Nippon India Nifty Pharma ETF2.03%
Mirae Asset Nifty 500 Healthcare ETF1.41%
Motilal Oswal BSE Healthcare ETF1.23%
HDFC Nifty Smallcap 250 ETF0.88%
Motilal Oswal Nifty Smallcap 250 ETF0.88%
Mirae Asset Nifty Smallcap 250 ETF0.88%
DSP Nifty Smallcap 250 ETF0.88%
Groww Nifty Smallcap 250 ETF0.87%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma